A Look At What Eye See

Dr. Clay Siegall, CEO of Seattle Generic

In an interview, Dr. Clay Siegall, explains what inspired him to start his business. He noted that he was interested in medicine, the reason to overcome diseases and the power of technology. He first developed an interest in cancer treatment while at the University of Maryland when studying zoology. One of his family members got sick and he did not like the treatment that was given. Instead, they developed severe anemia that could have led to death due to chemotherapy. He became aware of other treatment that involves radical surgery and amputation and thought to himself that there has to be a better way, and this was the starting point.

There are a number of ways that Dr. Clay Siegall makes money at Seattle Genetic. First, it is through the selling of their own proprietary drugs. For example, FDA drug is selling well. Another way is through production partnerships and also licensing of technologies and the processes that they have developed. Though he mentioned that there are some ways they are earning revenues. When it comes to profit, he said that it took about ten years to start making profits.

Dr. Clay Siegall says that hard work is what makes him successful. He referred to Charle Darwin’s letter to his cousin that showed men do not substantially differ in intellect but in the work habits. Therefore the views that having a passion to work intensely and with focus is what makes a person succeed. The other factors like IQ, where a person schooled are just secondary.

Dr. Clay Siegall attended The University of Maryland where he graduated with a B.S in zoology, he later went to George Washington University where he earned a Ph.D. in generics. He co-founded Seattle Genetics in 1998 and he holds the position of the president, CEO as well as the chairman of the board. He has helped the company to realize its current leadership position and as well as developing antibody-drug conjugates. In 2011, he saw FDA approving ADC first product, ADCETRIS, and with the collaboration with Takeda Pharmaceutical Company, ADCETRIS is a brand that is recognized worldwide having been approved in more than 65 countries.